Role of human carbonic anhydrase isoforms VA and VB in obesity: Implications, mechanisms, and therapeutic prospects

Year 2024, Volume: 28 Issue: 3, 733 - 748, 28.06.2025

Muhammet Kaçmaz Muhammed Trawally , Özlen Güzel Akdemir

https://izlik.org/JA55NZ34HU

Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes ubiquitous in both prokaryotes and eukaryotes and catalyze a very basic physiological reaction. In particular, hCA VA and hCA VB isoenzymes are mitochondrial isoforms that are involved in metabolic processes such as ureagenesis, gluconeogenesis, and de novo lipogenesis by providing bicarbonate. The development of inhibitors for hCA VA and hCA VB commenced following the observation of weight loss, a metabolic adverse effect, in epileptic patients who were using antiepileptic medicines such as topiramate, zonisamide, and acetazolamide. Based on the structures of these drugs, the rational drug design technique, together with the famous “tail approach” was applied to develop novel hCA VA and hCA VB inhibitors that have potential as anti-obesity drug candidates. This review summarizes the implication of hCA VA and hCA VB in the pathophysiology of obesity and the inhibitory activities of small molecules developed against hCA VA and hCA VB as potential anti-obesity agents.

Keywords

Carbonic anhydrase , obesity , lipogenesis , gluconeogenesis , mitochondrial enzymes

References

• [1] Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008; 7(2): 168–181. https://doi.org/10.1038/nrd2467.
• [2] Supuran CT, Scozzafava, A, Conway, J. Carbonic Anhydrase: Its Inhibitors and Activators, first ed., CRC Press, Boca Raton, FL, USA 2004.
• [3] Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003; 23(2): 146-189. https://doi.org/10.1002/med.10025.
• [4] Rakhra V, Galappaththy SL, Bulchandani S, Cabandugama PK. Obesity and the western diet: How we got here. Mo Med. 2020; 117(6): 536-538.
• [5] Solomon CG, Manson JAE. Obesity and mortality: A review of the epidemiologic data. Am J Clin Nutr. 1997; 66(4): 1044-1050. https://doi.org/10.1093/ajcn/66.4.1044S.
• [6] Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Lond). 2019; 19(3): 205–212. https://doi.org/10.7861/clinmedicine.19-3-205.
• [7] Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007; 15(13): 4336–4350. https://doi.org/10.1016/j.bmc.2007.04.020.
• [8] Maresca A, Vullo D, Scozzafava A, Supuran CT. Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions. J Enzyme Inhib Med Chem. 2013; 28(2): 388–391. https://doi.org/10.3109/14756366.2011.649268.
• [9] Rahman S, Bibi S, Javed T, Alam F, Ali A, Qureshi ZR, Ali S, Ullah M, Hassan Bin Asad MH, Hasan SMF, Sabatier JM, Rizvanoc AA. Review: Therapeutic potential of carbonic anhydrase inhibitors. Pak J Pharm Sci. 2019; 32(2): 709-720.
• [10] Stephens LC, Katz SG. Phentermine and Anaesthesia. Anaesth. 2005; 33(4): 525-527. https://doi.org/10.1177/0310057X0503300418.
• [11] Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, Wu SQ, Ye XF, Xu JF, He J. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PloS one. 2012; 7(6): e39062. https://doi.org/10.1371/journal.pone.0039062.
• [12] Hvizdos KM, Markham A. Orlistat. Drugs. 1999; 58: 743–760. https://doi.org/10.2165/00003495-199958040-00015.
• [13] Lim S, Rogers LK, Tessler O, Mundinger GS, Rogers C, Lau FH. Phentermine: A Systematic review for plastic and reconstructive surgeons. Ann Plast Surg. 2018; 81(4): 508. https://doi.org/10.1097/SAP.0000000000001478.
• [14] Sidhaye A, Cheskin LJ. Pharmacologic treatment of obesity. Adv Psychosom Med. 2006; 27: 42-52. https://doi.org/10.1159/000090962.
• [15] Rossi F, Punzo F, Umano GR, Argenziano M, Miraglia Del Giudice E. Role of cannabinoids in obesity. Int J Mol Sci. 2018; 19(9): 2690. https://doi.org/10.3390/ijms19092690.
• [16] Gadde KM. Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction. Curr Drug Targets. 2005; 5(6): 549–556. https://doi.org/10.2174/156800605774962095.
• [17] Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295(7): 761–775. https://doi.org/10.1001/jama.295.7.761.
• [18] Mariam Z, Niazi SK. Glucagon‐like peptide agonists: A prospective review. Endocrinol Diab Metab. 2024; e462. https://doi.org/10.1002/edm2.462.
• [19] Ding Y, Shi Y, Guan R, Yan S, Liu H, Wang Z, Li J, Wang T, Cai W, Ma G. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. Pharmacol Res 2023; 107031. https://doi.org/10.1016/j.phrs.2023.107031.
• [20] Lomelino CL, Supuran CT, McKenna R. Non-classical inhibition of carbonic anhydrase. Int J Mol Sci. 2016; 17(7): 1150. https://doi.org/10.3390/ijms17071150.
• [21] Guler OO, Simone GD, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem. 2010; 17(15): 1516-1526. https://doi.org/10.2174/092986710790979999.
• [22] Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int. 2007; 71(2): 103-115. https://doi.org/10.1038/sj.ki.5002020.
• [23] Lynch CJ, Fox H, Hazen SA, Stanley BA, Dodgson S, Lanoue KF. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995; 310(1): 197-202. https://doi.org/10.1042/bj3100197.
• [24] Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F, Sly WS. Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem. 2013; 21(6): 1570–1582. https://doi.org/10.1016/j.bmc.2012.04.044.
• [25] Chegwidden, WR. The Carbonic anhydrases in health and disease. In: Chegwidden WR, Carter ND, (Eds). The carbonic anhydrases: Current and emerging therapeutic targets. Springer, Cham, 2021, pp. 1-12
• [26] Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12): 1221–1234. https://doi.org/10.1016/S2214-109X(17)30393-5.
• [27] Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008; 14(7): 649-654. https://doi.org/10.2174/138161208783877866.
• [28] Sugrue M. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000; 19(1): 87-112. https://doi.org/10.1016/S1350-9462(99)00006-3.
• [29] Ciccone L, Cerri C, Nencetti S, Orlandini E. Carbonic anhydrase inhibitors and epilepsy: State of the art and future perspectives. Molecules. 2021; 26(21): 6380. https://doi.org/10.3390/molecules26216380.
• [30] Stoner A, Harris A, Oddone F, Belamkar A, Chandra A, Vercellin A, Shin J, Januleviciene, Siesky Brent. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? J Ophthalmol. 2022; 106: 1332-1337. https://doi.org/10.1136/bjophthalmol-2021-319530.
• [31] Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399(6733): 271-275. https://doi.org/10.1038/20459.
• [32] Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des. 2008; 14(7): 685-698. https://doi.org/10.2174/138161208783877893
• [33] Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev. 2007; 26(2): 223–224. https://doi.org/10.1007/s10555-007-9058-y.
• [34] Brahimi-Horn MC, Pouysségur J. Oxygen, a source of life and stress. FEBS Letters. 2007; 581(19): 3582-3591. https://doi.org/10.1016/j.febslet.2007.06.018.
• [35] Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim AV, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516): 468-472. https://doi.org/10.1126/science.1059796.
• [36] Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature. 2002; 417(6892): 975-978. https://doi.org/10.1038/nature00767.
• [37] Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012; 112(8): 4421-4468. https://doi.org/10.1021/cr200176r.
• [38] Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis and therapy. Eur Urol. 2010; 58(1): 75-83. https://doi.org/10.1016/j.eururo.2010.03.015.
• [39] Monti ST, Supuran CT, De Simone G. Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr Med Chem. 2012; 19(6): 821-830. https://doi.org/10.2174/092986712799034851.
• [40] Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007; 26(2): 299-310. https://doi.org/10.1007/s10555-007-9064-0.
• [41] Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med. 2000; 6(1): 15-19. https://doi.org/10.1016/S1357-4310(99)01615-9.
• [42] Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002; 8(4): 1284–1291.
• [43] Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem. 2007; 101(4): 937-949. https://doi.org/10.1002/jcb.21187.
• [44] Türeci Ö, Sahin U, Vollmar E, Siemer S, Göttert E, Seitz G, Parkkila AK, Shah GN, Grubb JH, Pfreundschuh M, Sly WS. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. PNAS. 1998; 95(13): 7608-7613. https://doi.org/10.1073/pnas.95.13.7608.
• [45] Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman M. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. PNAS. 1998; 95(21): 12596-12601. https://doi.org/10.1073/pnas.95.21.12596.
• [46] Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001; 158(3): 905–919. https://doi.org/10.1016/S0002-9440(10)64038-2.
• [47] Ilie MI, Hofman V, Ortholan C, Ammadi RE, Bonnetaud C, Havet K, Venissac N, Mouroux J, Mazure NM, Pouyssegur J, Hofman P. Overexpression of carbonic anhydrase XII in tissues from resectable non‐small cell lung cancers is a biomarker of good prognosis. Int J Cancer. 2011; 128(7): 1614-1623. https://doi.org/10.1002/ijc.25491.
• [48] Jeśman C, Młudzik A, Cybulska M. Historia odkrycia antybiotyków i sulfonamidów [History of antibiotics and sulphonamides discoveries]. Pol Merkur Lekarski. 2011; 30(179): 320-322.
• [49] Supuran, CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol. 2011; 2: 34. https://doi.org/10.3389/fphar.2011.00034.
• [50] Farzam K, Abdullah M. Acetazolamide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 2, 2023.
• [51] Kyllönen MS, Parkkila S, Rajaniemi H, Waheed A, Grubb JH, Shah GN, Sly WS, Kaunisto K. Localization of carbonic anhydrase XII to the basolateral membrane of H+-secreting cells of mouse and rat kidney. J Histochem Cytochem. 2003; 51(9): 1217-1224. https://doi.org/10.1177/002215540305100912.
• [52] Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004; 14(1); 217–223. https://doi.org/10.1016/j.bmcl.2003.09.062.
• [53] Owa T, Yokoi A, Yamazaki K, Yoshimatsu K, Yamori T, Nagasu T. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J Med Chem. 2002; 45(22): 4913–4922. https://doi.org/10.1021/jm0201060.
• [54] Talbot DC, Pawel J, Cattell E, Yule M, Johnston C, Zandvliet AS, Huitema ADR, Norbury CJ, Ellis P, Bosquee L, Reck M. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non–small cell lung cancer. Clin Cancer Res. 2007; 13 (6): 1816–1822. https://doi.org/10.1158/1078-0432.CCR-06-0249.
• [55] Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018; 8(2): 25. https://doi.org/10.3390/metabo8020025.
• [56] Aspatwar A, Supuran CT, Waheed A, Sly WS, Parkkila S. Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease. Physiol J. 2023; 601(2): 257-274. https://doi.org/10.1113/JP283579.
• [57] Tanc M, Carta F, Scozzafava A, Supuran CT. 6-Substituted 1, 2-benzoxathiine-2, 2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA. Org Biomol Chem. 2015; 13(1): 77-80. https://doi.org/10.1039/C4OB02155J.
• [58] Supuran CT, Mugelli A. Polypharmacology of carbonic anhydrase inhibitors. Pharmadvances. 2019; (1): 14-38. https://doi.org/10.36118/pharmadvances.00.2019.06
• [59] Parkkila S, Kivelä AJ, Kaunisto K, Parkkila AK, Hakkola J, Rajaniemi H, Waheed A, Sly WS. The plasma membrane carbonic anhydrase in murine hepatocytes identified as isozyme XIV. BMC Gastroenterol. 2002; (2): 1-7. https://doi.org/10.1186/1471-230X-2-13.
• [60] Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes. 2010; 17(5): 446. https://doi.org/10.1097%2FMED.0b013e32833c3026.
• [61] Shah GN, Hewett-Emmett D, Grubb JH, Migas MC, Fleming RE, Waheed A, Sly WS. Mitochondrial carbonic anhydrase CA VB: differences in tissue distribution and pattern of evolution from those of CA VA suggest distinct physiological roles. PNAS. 2000; 97(4): 1677-1682. https://doi.org/10.1073/pnas.97.4.1677.
• [62] Akdemir A, Güzel-Akdemir Ö. The structure, physiological role, and potential medicinal applications of carbonic anhydrase V. In: Supuran CT, Simone GD, (Eds). Carbonic anhydrases as biocatalysts: From theory to medical and industrial applications. Elsevier, 2015, pp 125–138.
• [63] Kalinin S, Supuran CT, Krasavin M. Multicomponent chemistry in the synthesis of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2016; 31(4): 185-199. https://doi.org/10.1080/14756366.2016.1220944.
• [64] Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000; 8(9): 656-663. https://doi.org/10.1038/oby.2000.84.
• [65] Vitale RM, Pedone C, Amodeo P, Antel J, Wurl M, Scozzafava A, Supuran CT, De Simone G. Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. Bioorg Med Chem. 2007: 15(12): 4152-4158. https://doi.org/10.1016/j.bmc.2007.03.070.
• [66] Ben‐Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate‐treated epilepsy. Obes Res. 2003; 11(4): 556-562. https://doi.org/10.1038/oby.2003.78.
• [67] Güzel Ö, Innocenti A, Scozzafava A, Salman A, Supuran CT. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem. 2009; 17(14): 4894-4899. https://doi.org/10.1016/j.bmc.2009.06.006.
• [68] Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021; 36(1): 1702–1714. https://doi.org/10.1080/14756366.2021.1945049.
• [69] Smaine FZ, Pacchiano F, Rami M, Barragan-Montero V, Vullo D, Scozzafava A, Winum JY, Supuran CT. Carbonic anhydrase inhibitors: 2-Substituted-1, 3, 4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorg Med Chem Lett. 2008; 18(24): 6332-6335. https://doi.org/10.1016/j.bmcl.2008.10.093.
• [70] Poli G, Bozdag M, Berrino E, Angeli A, Tuccinardi T, Carta F, Supuran CT. N-aryl-N′-ureido-O-sulfamates as potent and selective inhibitors of hCA VB over hCA VA: Deciphering the binding mode of new potential agents in mitochondrial dysfunctions. Bioorg Chem. 2020; 100; 103896. https://doi.org/10.1016/j.bioorg.2020.103896.
• [71] Supuran CT. Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. J Enzyme Inhib Med Chem. 2022;37(1):2478-2488. https://doi.org/10.1080/14756366.2022.2121393.
• [72] Maresca A, Supuran CT. (R)-/(S)-10-Camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases. BioorG Med Chem Lett. 2011; 21(5): 1334-1337. https://doi.org/10.1016/j.bmcl.2011.01.050.
• [73] Poulsen SA, Wilkinson BL, Innocenti A, Vullo D, Supuran CT. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008; 18(16): 4624-4627. https://doi.org/10.1016/j.bmcl.2008.07.010.
• [74] Carta F, Birkmann A, Pfaff T, Buschmann H, Schwab W, Zimmermann H, Maresca A, Supuran CT. Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action. J Med Chem. 2017; 60(7) 3154-3164. https://doi.org/10.1021/acs.jmedchem.7b00183.
• [75] Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004; 47(5): 1272-1279. https://doi.org/10.1021/jm031057.
• [76] Das Mahapatra A, Queen A, Yousuf M, Khan P, Hussain A, Rehman MT, Alajmi MF, Datta B, Hassan MI . Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: Towards therapeutic management of diabetes and obesity. J Biomol Struct Dyn. 2022; 40(7): 3144–3154. https://doi.org/10.1080/07391102.2020.1845803.
• [77] Tanini D, Capperucci A, Locuoco M, Ferraroni M, Costantino G, Angeli A, Supuran CT. Benzoselenoates: A novel class of carbonic anhydrase inhibitors. Bioorg Chem. 2022; 122: 105751. https://doi.org/10.1016/j.bioorg.2022.105751.
• [78] Costa G, Gidaro MC, Vullo D, Supuran CT, Alcaro S. Active components of essential oils as anti-obesity potential drugs investigated by in silico techniques. J Agric Food Chem. 2016; 64(26): 5295-5300. https://doi.org/10.1021/acs.jafc.6b02004.